Investigation on the Chronic Effects of Nepalese Pepper (Zanthoxylum Armatum DC) on Cognitive Function, Mood and Gaming Performance in Young, Healthy, Action Video Gamers
NCT07752329, Not applicable, Not yet recruiting, Northumbria University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Investigation on the Chronic Effects of Nepalese Pepper (Zanthoxylum Armatum DC) on Cognitive Function, Mood and Gaming Performance in Young, Healthy, Action Video Gamers | ClinicalTrials.gov |
| NCT number | NCT07752329 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 70 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Northumbria University | ClinicalTrials.gov |
| Conditions | Cognition, Mood, Gaming Performance, Fatigue | ClinicalTrials.gov |
| Interventions | Nepalese Pepper (Zanthoxylum Armatum DC) extract 275mg, Placebo | ClinicalTrials.gov |
| First posted | 2026-08-07 | ClinicalTrials.gov |
| Last updated | 2026-08-07 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Subjective Fatigue | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Self-assessed fatigue level following each of three completions of the Cognitive Demand Battery (CDB). | ClinicalTrials.gov |
| Primary | Speed of Performance | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Composite outcome derived from combined performance on Serial 3 Subtractions, Simple Reaction Time, Choice Reaction Time, Numeric Working Memory, RVIP, Delayed Picture Recognition, and Delayed Word Recognition tasks from the COMPASS battery. | ClinicalTrials.gov |
| Secondary | Accuracy of Attention | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through combined performance on Rapid Visual Information Processing, RVIP, and Choice Reaction Time tasks. | ClinicalTrials.gov |
| Secondary | Speed of Attention | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through combined performance on Rapid Visual Information Processing, Simple Reaction Time, and Choice Reaction Time tasks. | ClinicalTrials.gov |
| Secondary | Accuracy of Performance | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through combined performance on Immediate Word Recall, Choice Reaction Time, Corsi Blocks, Stroop, RVIP, Delayed Word Recall, Delayed Picture Recognition, and Delayed Word Recognition. | ClinicalTrials.gov |
| Secondary | Working Memory | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through combined performance on Numeric Working Memory and Corsi Blocks tasks. | ClinicalTrials.gov |
| Secondary | Speed of Memory | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through combined performance on Numeric Working Memory, Delayed Picture Recognition, and Delayed Word Recognition tasks. | ClinicalTrials.gov |
| Secondary | Episodic Memory | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through combined performance on Immediate Word Recall, Delayed Word Recall, Delayed Picture Recognition, and Delayed Word Recognition tasks. | ClinicalTrials.gov |
| Secondary | Executive Function | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Score calculated through performance on Peg and Ball and Stroop interference tasks. | ClinicalTrials.gov |
| Secondary | Mood | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Mood rating calculated through answers to the Visual Analogue Mood Scales and the Positive and Negative Affect Schedule. | ClinicalTrials.gov |
| Secondary | Sleep Disturbance | Assessed on the Baseline and Endpoint visit of each 42-day treatment arm. | Sleep disturbance score calculated through the PROMIS Sleep Disturbance Short Form (8 items, range 8-40, higher scores indicating greater disturbance). | ClinicalTrials.gov |
| Secondary | Heart Rate Variability (HRV) | Assessed at rest upon arrival, prior to task performance or supplementation, on the Baseline and Endpoint visit of each 42-day treatment arm. | HRV recorded via a 5-minute resting ECG using Biopac research rings, following 5 minutes of seated rest, prior to any task performance or supplementation. | ClinicalTrials.gov |
| Secondary | First Person Shooter Aiming Ability | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Aiming performance with a mouse measured through accuracy percentage and reaction time across five Aim Labs challenges (Spidershot, Motionshot, Gridshot, CircleShot, WallPeek). | ClinicalTrials.gov |
| Secondary | MOBA Control Ability | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Measure of character control ability using a custom MOBA-style game, indexed by in-game score, reaction time, accuracy, targets hit, distance travelled, and click patterns. | ClinicalTrials.gov |
| Secondary | Multi-Tasking Ability | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Multi-tasking ability measured through Multi-Tasking Framework score. | ClinicalTrials.gov |
| Secondary | Finger Tapping Task | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Number of finger taps completed in 10 seconds. | ClinicalTrials.gov |
| Secondary | Fitts' Law Task | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Visuomotor speed-accuracy trade-off measured through throughput (bits/second; effective index of difficulty divided by movement time, averaged as a mean of condition means), with slope and intercept of the movement-time-on-ID regression as secondary parameters. | ClinicalTrials.gov |
| Secondary | Multiple Object Tracking Task | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Divided visual attention measured through threshold tracking speed, estimated via a staircase procedure. | ClinicalTrials.gov |
| Secondary | Collision Prediction Task | Assessed at pre-dose baseline and 1hr post-dose, on the Baseline and Endpoint visit of each 42-day treatment arm. | Anticipation and trajectory prediction measured through spatial prediction error (Euclidean distance between click position and true collision point, in pixels) and temporal prediction error (absolute deviation between click timing and true collision time, in milliseconds). | ClinicalTrials.gov |
| Secondary | Subjective Gameplay Performance | At home, periodically throughout each 42-day supplementation period, following gameplay sessions. | Subjective Performance Gameplay Scale self-report, completed by participants following evening gameplay sessions. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 9
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Choice Reaction Time | Primary outcome | ConductCognition |
| Simple Reaction Time | Primary outcome | ConductCognition |
| Corsi Block-Tapping Test | Secondary outcome | ConductCognition |
| Delayed Recall Module | Secondary outcome | ConductCognition |
| Finger Tapping Task | Secondary outcome | ConductCognition |
| Fitts Pointing Task | Secondary outcome | ConductCognition |
| Multiple Object Tracking | Secondary outcome | ConductCognition |
| Rapid Visual Information Processing | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)